{"id":"NCT00774345","sponsor":"Celgene","briefTitle":"A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01-27","primaryCompletion":"2020-10-27","completion":"2020-10-27","firstPosted":"2008-10-17","resultsPosted":"2021-12-02","lastUpdate":"2021-12-02"},"enrollment":317,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["B-cell Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":["Revlimid"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Experimental: 1","type":"EXPERIMENTAL"},{"label":"Placebo Comparator: 2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 11 years","effectByArm":[{"arm":"Lenalidomide","deltaMin":95.09,"sd":null},{"arm":"Placebo","deltaMin":73.28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.276"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":241,"countries":["United States","Australia","Austria","Belgium","Canada","Colombia","Czechia","Denmark","France","Germany","Hungary","Ireland","Israel","Italy","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28958469"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":158},"commonTop":["Neutropenia","Fatigue","Diarrhoea","Cough","Thrombocytopenia"]}}